tbuckley/cabot-search huggingface dataset:
NIMG-46. IMPACT OF FET PET ON MULTIDISCIPLINARY NEUROONCOLOGICAL TUMOR BOARD DECISIONS IN PATIENTS WITH BRAIN TUMORS
Authors: Garry Ceccon, Jan-Michael Werner, Maximilian Ruge, Jürgen Hampl, Stefan Grau, Roland Goldbrunner, Eren Celik, Christian Reinhardt, Christoph Kabbasch, Jan Borggrefe, Elena Bauer, Michael Wollring, Jurij Rosen, Caroline Tscherpel, Gereon Fink, Karl-Josef Langen, Norbert Galldiks
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Following neurooncological treatment of brain tumors, neurooncologists are frequently confronted with equivocal MRI findings (e.g., treatment-related changes, nonmeasurable (speckled) contrast-enhancing lesions, increase of T2/FLAIR signal alterations, pseudoresponse). Especially in Europe, amino acid PET is increasingly being integrated into multidisciplinary neurooncological tumor boards (MNTB) to overcome these diagnostic uncertainties as well as to improve patient management. We here evaluated the correctness of MNTB decisions, in which amino acid PET findings were taken into account. METHODS In a single university center, we retrospectively evaluated 114 MNTB decisions concerning 99 patients with malignant glioma (n=81) (glioblastoma, n=54; anaplastic glioma, n=26; gliosarcoma, n=1) or brain metastases (n=18) secondary to NSCLC, melanoma, breast cancer, or colorectral cancer, presenting with equivocal MRI findings following neurooncological treatment. All patients underwent amino acid PET imaging using O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) as an adjunct for decision-making. Additionally, the patients’ clinical status, pretreatment, and multimodal MRI findings were considered for decision-making. Presence of neoplastic tissue in PET was considered if the mean FET uptake as assessed by tumor-to-brain ratios was &gt;2. The decisions’ diagnostic performance was evaluated by 2x2 contingency tables using the neuropathological results or clinicoradiological follow-up. RESULTS In the majority of MNTB decisions (n=102; 89%), FET PET results were integrated into the decision-making with considerable impact on the clinical management. In particular, 85% of MNTB decisions (n=87) prompted a treatment change (i.e., resection, radiotherapy, chemotherapy, or combinations thereof, as well as palliative therapy), or, in the case of suspected treatment-related changes, the continuation of the initial treatment regimen (15%; n=15). The MNTB decisions were validated using neuropathological data in 38% (n=39) or clinicoradiological information in 62% (n=63) and yielded a diagnostic accuracy of 88% (sensitivity, 89%; specificity, 75%; P=0.008). CONCLUSIONS Our results suggest that the integration of FET PET derived information significantly aids MNTB decisions.
LSC 2013 abstract - Unravelling VEGF 165 signalling in the lung
Authors: Khadija Ourradi, Thomas Blythe, Shaney Barratt, Caroline Jarett, Gavin Welsh, Ann Millar
Journal: European Respiratory Journal (2013)

Vascular endothelial growth factor (VEGF) is a potent mitogenic, angiogenic and permeability factor implicated in both the development of lung injury and repair in several respiratory diseases such as ARDS and IPF. VEGF 165  acts through VEGF receptors in particular VEGFR-2, leading to a complex network of signalling pathways resulting in changes to cell permeability, migration and proliferation; unexplored in the lung. We have investigated the downstream signalling mechanisms regulated by VEGF 165  in pulmonary and systemic endothelial cells.  HUVEC and Human Lung Microvascular Endothelial Cells (HMVEC-L) were treated with VEGF 165 . Phosphorylations of VEGFR-2 (tyr 1175  and tyr 1214 ) were measured along with phosphorylation/activation of pMEK1/2, p44/42MAPK (regulating cell proliferation) and eNOS protein (involved in cell permeability). The downstream effects of VEGF 165  on cell permeability was assessed by Endohm, Electrical Cell-Substrate Impedance Sensor (ECIS) and FITC-BSA passage and changes in VE-cadherin cell distribution was determined by immunofluorescence.  Phosphorylation of VEGFR-2 at tyr 1175  and tyr 1214  was induced between 2 and 10min (5 fold increase). Activation of pMEK1/2 and p44/42MAPK showed a similar time course to that of VEGFR-2 (>5 fold). Phosphorylation of eNOS was also observed (>2 fold) and indeed VEGF 165  increased cell permeability in both cell types (Huvec p  VEGF 165  induces responses in HUVEC and HMVEC-L cell behaviour suggesting different pathways for the regulation of mitogenesis or permeability identifying potential therapeutic targets.
FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study
Authors: Patrick A. Brown, John Kairalla, Joanne M. Hilden, Zoann Eckert Dreyer, Andrew J. Carroll, Nyla A. Heerema, Cindy Wang, Meenakshi Devidas, William L. Carroll, Elizabeth A. Raetz, Mignon L. Loh, Stephen P. Hunger, Michael J. Borowitz, Donald Small
Journal: Blood (2019)
Ibrutinib, Venetoclax Plus Obinutuzumab in Newly Diagnosed Mantle Cell Lymphoma Patients
Authors: Steven Le Gouill, Franck Morschhauser, Kamal Bouabdallah, Guillaume Cartron, Olivier Casasnovas, Thomas Gastinne, Patrice Chevallier, Cédric Rossi, Emmanuelle Tchernonog, Rory McCulloch, Charles Herbaux, David Chiron, Mary Callanan, Simon Rule
Journal: Blood (2019)
Polio outbreak: officials deny reports of cover-up in Pakistan
Authors: Ashfaq Yusufzai
Journal: BMJ (2019)

Pakistan has launched a fresh campaign to increase the uptake of polio vaccine, after the vaccine derived poliovirus type 2 (VDPV2) was detected in seven children in August.

The Pakistani government and the World Health Organization were not initially informed of the outbreak of the vaccine derived virus, which was thought to have been eliminated in 2014. But the federal health minister, Zafar Mirza, denied any attempt to conceal the outbreak. “There was no cover-up as we were waiting for full confirmation of the virus,” he told The BMJ .

To mitigate the associated risks, the Pakistan Polio programme …
Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability
Authors: Alessandra Pompa, Concetta Conticello, Diana Giannarelli, Loredana Pettine, Laura Paris, Lucia Tognazzi, Magda Marcatti, Elisabetta Antonioli, Francesca Fioritoni, Angela Bonalumi, Silvia Mangiacavalli, Paola Bertazzoni, Iolanda Donatella Vincelli, Daniele Derudas, Agostina Siniscalchi, Sara Pezzatti, Renato Zambello, Annalisa Citro, Angelo Belotti, Alessandra Lombardo, Federico Vozella, Adelina Sementa, Ugo Consoli, Alfredo Molteni, Niccolò Frungillo, Massimo Gentile, Gabriele Buda, Sara Aquino, Salvatore Palmieri, Velia Bongarzoni, Alessandro Inzoli, Valeria Ferla, Francesca Gaia Rossi, Valerio Leotta, Alessandra Romano, Federica Elia, Vittorio Del Fabro, Guido Montanaro, Francesca Cavallaro, Monica Galli, Luca Baldini
Journal: Blood (2019)
Association of Testosterone Therapy With Risk of Venous Thromboembolism Among Men With and Without Hypogonadism
Authors: Rob F. Walker, Neil A. Zakai, Richard F. MacLehose, Logan T. Cowan, Terrence J. Adam, Alvaro Alonso, Pamela L. Lutsey
Journal: JAMA Internal Medicine (2019)

Testosterone therapy is increasingly prescribed in patients without a diagnosis of hypogonadism. This therapy may be associated with increased risk of venous thromboembolism (VTE) through several mechanisms, including elevated hematocrit levels, which increase blood viscosity.
DNA Damage Repair Interference By WEE1 Inhibition with AZD1775 Overcomes Combined Azacitidine and Venetoclax Resistance in Acute Myeloid Leukmeia (AML)
Authors: Raoul Tibes, Diego Ferreira Coutinho, Michael Tuen Tuen, Xufeng Chen, Christina Glytsou, Ioannis Aifantis, Sergey Shmelkov
Journal: Blood (2019)
Treatment of Adults with Minimal Residual Disease (MRD) Positive Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study
Authors: Nicolas Boissel, Renato Bassan, Josep-Maria Ribera, Sabina Chiaretti, Robin Foà, Cristina Papayannidis, Naufil Alam, Alessandra Brescianini, Isabella Pezzani, Georg Kreuzbauer, Alessandro Rambaldi
Journal: Blood (2019)
QOLP-26. PATIENT REPORTED SOCIAL FUNCTION AND SURVIVAL IN GLIOMA PATIENTS
Authors: Sara Hardy, Chintan Pandya, Nimish Mohile, Michelle Janelsins, Michael Milano
Journal: Neuro-Oncology (2019)

Abstract PURPOSE Research among patients with cancer suggests that health related quality of life (HRQOL) may be more predictive of survival than performance status. Social function is a HRQOL outcome influenced by both physical and mental health. To our knowledge, no work has analyzed the potential association between survival and social function in patients with brain tumors. METHODS In the SEER Medicare Health Outcomes Survey, 158 patients were identified with 1) diagnosis of glioma between 1976 and 2013 2) no other cancer diagnosis 3) at least one post-diagnosis HRQOL survey. We examined the relationship between social function and mortality using a multivariable Cox proportional hazard model. We also examined factors correlated with social function score using linear regression. RESULTS At last follow up, 48% of the patients had died, 53% were female, 59% had trouble with ≥1 ADL, 53% were married, 27% had glioblastoma, 74% were white, and 32% had no reported comorbidities. Median time from cancer diagnosis to survey was 79 months and median age at survey was 60 years. For patients alive at last follow-up, there was a difference of &gt;5 points for the social function subscale (38.2 vs 30.6) compared to those who died during the median 163 month follow up interval. On multivariable Cox proportion hazard model adjusting for covariates, higher social function scores were significantly associated with improved survival (5 point increase in score, HR 0.86, p = 0.0029). Worse social function was associated with patient-reported neurologic deficits in vision and speech and report of depression, but not marital status, sex, race, or patient-reported income. DISCUSSION Patient-reported social function score on post-diagnosis surveys, even after accounting for important clinical factors, was significantly associated with survival. The impact of patient reported social function in those with glioma should be further examined in confirmatory longitudinal studies.
2020 Update to the 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter
Authors: Paul A. Heidenreich, N. A. Mark Estes, Gregg C. Fonarow, Corrine Y. Jurgens, Michelle M. Kittleson, Joseph E. Marine, David D. McManus, Robert L. McNamara
Journal: Journal of the American College of Cardiology (2020)
Lactate Dehydrogenase to Carboxyhemoglobin Ratio As a Biomarker of Heme Release to Heme Processing Is Associated with Higher Tricuspid Regurgitant Jet Velocity and Early Death in Sickle Cell Disease
Authors: Annelies J. Van Vuren, Laurel Mendelsohn, Richard van Wijk, Caterina P. Minniti, John Baird, Gregory J Kato, Eduard J. van Beers
Journal: Blood (2019)
Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis
Authors: Zhaobing Ding, Russell E. Ericksen, Nathalie Escande-Beillard, Qian Yi Lee, Abigail Loh, Simon Denil, Michael Steckel, Andrea Haegebarth, Timothy Shen Wai Ho, Pierce Chow, Han Chong Toh, Bruno Reversade, Sylvia Gruenewald, Weiping Han
Journal: Journal of Hepatology (2019)
A defect in endothelial autophagy occurs in patients with non-alcoholic steatohepatitis and promotes inflammation and fibrosis
Authors: Adel Hammoutene, Louise Biquard, Juliette Lasselin, Marouane Kheloufi, Marion Tanguy, Anne-Clémence Vion, Jules Mérian, Nathalie Colnot, Xavier Loyer, Alain Tedgui, Patrice Codogno, Sophie Lotersztajn, Valérie Paradis, Chantal M. Boulanger, Pierre-Emmanuel Rautou
Journal: Journal of Hepatology (2019)
The BH3-Mimetic Obatoclax Restores the Response to Dexamethasone in Glucocorticoid-Resistant ALL through Induction of Autophagy.
Authors: Laura Bonapace, Beat C. Bornhauser, Gunnar Cario, Martin Schrappe, Felix Niggli, Beat W. Schaefer, Jean-Pierre Bourquin
Journal: Blood (2007)
Decreasing and stabilising trends of antimicrobial consumption and resistance in Escherichia coli and Klebsiella pneumoniae in segmented regression analysis, European Union/European Economic Area, 2001 to 2018
Authors: Germán Peñalva, Liselotte Diaz Högberg, Klaus Weist, Vera Vlahović-Palčevski, Ole Heuer, Dominique L Monnet
Journal: Eurosurveillance (2019)

Investments to reduce the spread of antimicrobial resistance (AMR) in the European Union have been made, including efforts to strengthen prudent antimicrobial use. Using segmented regression, we report decreasing and stabilising trends in data reported to the European Surveillance of Antimicrobial Consumption Network and stabilising trends in data reported to the European Antimicrobial Resistance Surveillance Network. Our results could be an early indication of the effect of prioritising AMR on the public health agenda.
Pattern of Somatic Mutation Changes from Diagnosis to Relapse Following Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)
Authors: Sanghee Hong, Cassandra M Kerr, Lisa Rybicki, Valeria Visconte, Jibran Durrani, Hassan Awada, Betty K. Hamilton, Ronald Sobecks, Matt Kalaycio, Aaron T. Gerds, Mikkael A. Sekeres, Hetty E. Carraway, Sudipto Mukherjee, Anjali S. Advani, Aziz Nazha, Navneet S. Majhail, Jaroslaw P. Maciejewski
Journal: Blood (2019)
Systemic Lupus Erythematosus
Authors: A. S. Townes
Journal: JAMA (1977)

This small, readable volume provides a clinical review of systemic lupus erythematosus (SLE), but it is primarily a report of the author's experience with 142 patients with this disease seen at the Massachusetts General Hospital between 1932 and 1966 and a statement of her opinions about the disease and its management based on that experience. This group of patients is remarkable because of the length of follow-up and the observations recorded in many patients with major organ involvement without corticosteroid treatment. The author's principal message is clear: that the course of SLE is highly variable and unpredictable, with a favorable outlook for survival for ten years or more in the majority of cases; that remissions occur and may be prolonged without corticosteroid therapy; and that rigorous proof is lacking of the efficacy of toxic drugs, including corticosteroids, in extending survival. The "conservative" program of treatment that the author advocates, using
PATH-48. THE DNA METHYLATION LANDSCAPE OF CORE AND PERIPHERAL DIFFUSE GLIOMA REGIONS SHOWS LITTLE SPATIAL SUBTYPE HETEROGENEITY AFTER CONSIDERING TUMOR PURITY
Authors: Niels Verburg, Floris Barthel, Kevin Anderson, Thomas Koopman, Maqsood Yaqub, Otto Hoekstra, Adriaan Lammertsma, Frederik Barkhof, Petra Pouwels, Jaap C Reijneveld, Jan Heijmans, Annemieke Rozemuller, Joseph Costello, Michael Taylor, William Vandertop, Ronald Boellaard, Kevin C Johnson, Pieter Wesseling, Philip de Witt Hamer, Roel Verhaak
Journal: Neuro-Oncology (2019)

Abstract While diffuse gliomas are notorious for their histopathological, genetic and transcriptional spatial heterogeneity, little is known about their epigenetic spatial heterogeneity. The result of spatial (epi)genetic analysis is strongly influenced by the proportion of cancer cells in a sample, so called tumor purity. However, a gold standard for assessment of tumor purity is lacking. We set out to analyze tumor purity using different measurement modalities and explore tumor purity-corrected DNA methylation spatial heterogeneity in glioma. DNA methylation(-derived), quantitative histological and radiological measurements of tumor purity, as well as DNA methylation profiles, were analyzed in 133 image-guided multi-sector stereotactic biopsy samples of 16 patients with newly diagnosed glioma. These biopsies were acquired in regions with and without abnormalities on MRI. Data was validated in two independent populations of respectively 102 multi-region samples in 24 glioma patients and 64 single-region samples from patients without glioma. DNA methylation profiles from The Cancer Genome Atlas and the patients without glioma was used to predict DNA methylation and transcriptional subtype. Consensus measurement of tumor purity estimates (CPE) ranged from 0 to 91% and was most correlated with the DNA methylation measurement of tumor purity. Neuropathological qualitative assessment of tumor presence generally corresponded well with CPE, but occasionally samples reported as ‘histologically normal’ demonstrated tumor purities up to 53%. After filtering specimens with tumor purity less than 50%, DNA methylation subtype showed little spatial heterogeneity, this in contrast to transcriptional subtype. Samples from core and peripheral regions showed similar DNA methylation profiles. Non-purity related intratumoral heterogeneity for promotor methylation of epigenetically regulated genes was minimal, but higher in IDH-wildtype than in IDH-mutant gliomas. In conclusion, after considering DNA methylation-based measurement of tumor purity DNA methylation in diffuse gliomas shows little spatial heterogeneity; incorporating such tumor purity information can further increase the reliability of methylation-profiling-based tumor classification.
Mendelian Inheritance in Man: Catalogs of Autosomal Dominant, Autosomal Recessive, and X-Linked Phenotypes
Authors: H. Eldon Sutton
Journal: JAMA (1967)

This publication results from a very ambitious project—the cataloguing of all known inherited traits of man. That Dr. McKusick achieved a large measure of success is a tribute to his ability to organize masses of material. In order to accomplish this, the information was stored in a computer, and the printout was photographed directly for publication. In a brief introduction, Dr. Mc-Kusick explains his nosological philosophy: "They are either the<i>same</i>disease, if they are based on the same mutation, or they are<i>different</i>diseases." [Italics his.] It is subsequently apparent that this is meant literally; detectably different alleles (eg, the hemoglobin variants) are each given a separate entry. The main part of the text consists of 2,487 entries, including preferred and alternate trait designations, principal features of the phenotype, and selected references. The first "catalog" lists autosomal dominant traits, the second autosomal recessives, and the third X-linked recessives. Entries
Graft-Versus Host Disease Prophylaxis with Postransplantation Bendamustine in Refractory Leaukemia Patients
Authors: Ivan S Moiseev, Sergey N. Bondarenko, Elena I Darskaya, Aleksandr Alyanski, Evgeniya Borzenkova, Anna Dotcenko, Olga Kudyasheva, Sergey Lapin, Elena Surkova, Varvara Nikolaevna Ovechkina, Olga Vladislavovna Pirogova, Valentina Vladimirovna Porunova, Axel Zander, Boris Afanasyev
Journal: Blood (2019)
Factors Associated with Mortality in Patients Experiencing First Episodes of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). Results of the Spanish TTP Registry
Authors: Julio del Rio-Garma, Sabela Bobillo, Javier De La Rubia, Maria Cristina Pascual Izquierdo, Faustino García-Candel, Jose Maria Garcia-Gala, Reyes Gonzalez, Jose A Garcia-Erce, Laura Abril, Julia Vidan, Maria J Gomez-Vazquez, Francisco Peña, Cristina Arbona, Gemma Moreno Jiménez, Iñigo Romon, Ana Oliva, Aurora Viejo, Monica Linares, Ramón Salinas, Sonia Perez-Gonzalez, Arturo Pereira
Journal: Blood (2019)
Predictors of the Rowland Universal Dementia Assessment Scale (RUDAS) Performance in Adults with Sickle Cell Disease
Authors: Stéphanie Forté, Florence Blais, Mathias Castonguay, Nafanta Fadiga, Richard Ward, Béland Sébastien, Melanie Cohn, Denis Soulières, Kevin H. M. Kuo
Journal: Blood (2019)
A randomized phase II trial of adjuvant chemotherapy with uracil / tegafur (UFT) and gemcitabine (GEM) vs. gemcitabine alone in patients with resected pancreatic cancer
Authors: H. Yoshitomi, A. Togawa, F. Kimura, H. Shimizu, H. Yoshidome, M. Miyazaki
Journal: Journal of Clinical Oncology (2007)

4542 Background: GEM is now the standard therapy for patients with advanced pancreatic cancer (PC). However, there have been few randomized studies of adjuvant chemotherapy with GEM in patients with resected PC. Methods: Patients with invasive ductal pancreatic cancer who underwent radical surgery were enrolled. Within 8weeks after operation, pts were randomized to receive UFT and GEM (GU) or GEM alone (G). GEM was administrated at a dosage of 1g/m 2 IV weekly X3 out of 4weeks and UFT at a dosage of 200mg/body/day orally continuously. Eligibility included histological residual tumor (R) 0 or 1, and no previous chemo- or/and radiation therapy. Primary endpoint was 1y disease free survival (DFS) rate and secondary endpoints included overall survival (OS) and side effects in both groups. Results: Between 05/02 and 12/05, 100 patients were randomized into the two arms of the trial (50 pts to GU and 50 to G). No pts were found to be ineligible. Pts characteristics were well balanced (GU/G) with regard to median age (62/63y), tumor status (T3+4 88/94%), nodal status (N positive 77/72%), histological residual tumor status (R0 76/68%). Until 03/06, 1y DFS rate was 50.3% in GU and 45.5% in G and there was no significant difference between two groups. The median OS was 20m in GU and 28m in G (Log rank test: N.S.). Grade 2 or more toxicities were observed in 67.3% of GU pts and 56.3% of G pts (N.S.). No grade 4 or more toxicity was observed in either groups. Leucocytopenia was the most frequently observed side effect in both groups (Grade 2 or more GU/G 49/46%). Conclusion: Preliminary results confirm the efficacy and safety of GEM based adjuvant chemotherapy for pts with resected PC, but addition of UFT with GEM dose not improve DFS as compared with GEM alone, so far. Final results will be presented at the meeting. No significant financial relationships to disclose.